These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1711 related items for PubMed ID: 9134650

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
    Trusen B, Ries M, Zenker M, Rauh M, Beinder E, Keuper H, Harms D.
    Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
    [Abstract] [Full Text] [Related]

  • 3. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D, Stassen JM, Yasuda T, Refino C, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK.
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A, Ruusuvaara L.
    Thromb Haemost; 1988 Dec 22; 60(3):361-4. PubMed ID: 3149043
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC.
    Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946
    [Abstract] [Full Text] [Related]

  • 9. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
    Onundarson PT, Francis CW, Marder VJ.
    J Lab Clin Med; 1992 Jul 20; 120(1):120-8. PubMed ID: 1613318
    [Abstract] [Full Text] [Related]

  • 10. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
    Robbie LA, Booth NA, Croll AM, Bennett B.
    Thromb Haemost; 1993 Aug 02; 70(2):301-6. PubMed ID: 8236139
    [Abstract] [Full Text] [Related]

  • 11. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.
    Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D.
    Thromb Haemost; 1992 Jul 06; 68(1):60-3. PubMed ID: 1514173
    [Abstract] [Full Text] [Related]

  • 12. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
    van Giezen JJ, Boon GI, Jansen JW, Bouma BN.
    Thromb Haemost; 1993 Apr 01; 69(4):381-6. PubMed ID: 8497851
    [Abstract] [Full Text] [Related]

  • 13. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator.
    Huber K, Beckmann R, Rauscha F, Probst P, Kaindl F, Binder BR.
    Z Kardiol; 1993 Apr 01; 82 Suppl 2():195-200. PubMed ID: 8328203
    [Abstract] [Full Text] [Related]

  • 14. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV, Barrertt-Bergshoeff M, Hekkenberg RT, Rijken DC.
    Thromb Haemost; 1999 Apr 01; 81(4):605-12. PubMed ID: 10235448
    [Abstract] [Full Text] [Related]

  • 15. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
    Spriggs D, Gold HK, Hashimoto Y, Van Houtte E, Vermylen J, Collen D.
    Thromb Haemost; 1989 Feb 28; 61(1):93-6. PubMed ID: 2501892
    [Abstract] [Full Text] [Related]

  • 16. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D, Kremplewska-Nalezyta E, Gadomska G, Zastawna E, Michalski A, Drewniak W.
    Med Sci Monit; 2000 Aug 02; 6(4):684-91. PubMed ID: 11208392
    [Abstract] [Full Text] [Related]

  • 20. The effect of 40 kHz ultrasound on tissue plasminogen activator-induced clot lysis in three in vitro models.
    Pieters M, Hekkenberg RT, Barrett-Bergshoeff M, Rijken DC.
    Ultrasound Med Biol; 2004 Nov 02; 30(11):1545-52. PubMed ID: 15588966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 86.